Literature DB >> 1418692

Adverse drug reactions to systemic antifungals. Prevention and management.

J R Perfect1, M H Lindsay, R H Drew.   

Abstract

Systemic administration of antifungal agents for invasive mycoses has dramatically increased over the past 10 years in many fields of medicine. The increase has been due both to an increasing immune compromised population and to potent antibacterial agents which allow these fungi to invade tissue. It is apparent that our understanding of the use of both the old and new antifungal agents has significantly increased in the last few years. In this review, we attempt to document our extensive knowledge of the adverse effects of the polyenes, flucytosine, griseofulvin and azoles when given systemically for treatment. Interwoven in this documentation of the adverse reactions to these agents is the attempt to help clinicians potentially avoid some of these adverse effects and if they do occur, to be able to identify and successfully manage them.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1418692     DOI: 10.2165/00002018-199207050-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  295 in total

1.  Anaphylactic reaction after oral fluconazole.

Authors:  G Neuhaus; N Pavic; M Pletscher
Journal:  BMJ       Date:  1991-06-01

2.  Red man syndrome associated with amphotericin B.

Authors:  M E Ellis; W Tharpe
Journal:  BMJ       Date:  1990-06-02

3.  Itraconazole and anti-tuberculosis drugs.

Authors:  M Blomley; E L Teare; A de Belder; Y Thway; M Weston
Journal:  Lancet       Date:  1990-11-17       Impact factor: 79.321

4.  Hypokalaemia in patients with acute myeloid leukaemia after treatment with fluconazole.

Authors:  D Kidd; E A Ranaghan; T C Morris
Journal:  Lancet       Date:  1989-05-06       Impact factor: 79.321

5.  Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy.

Authors:  T R Best; J K Jenkins; F Y Murphy; S A Nicks; K L Bussell; D L Vesely
Journal:  Am J Med       Date:  1987-03-23       Impact factor: 4.965

Review 6.  Pharmacology of the allylamines.

Authors:  J E Birnbaum
Journal:  J Am Acad Dermatol       Date:  1990-10       Impact factor: 11.527

7.  Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans.

Authors:  R Negroni; O Palmieri; F Koren; I N Tiraboschi; R L Galimberti
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

8.  Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.

Authors:  A M Sugar; C Saunders
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

Review 9.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

10.  In-vivo effects of itraconazole on hepatic mixed-function oxidase.

Authors:  Z Damanhouri; M Gumbleton; P J Nicholls; M A Shaw
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

View more
  13 in total

Review 1.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

2.  Strong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi.

Authors:  Masaru Matsumoto; Kazuya Ishida; Akihiro Konagai; Kazunori Maebashi; Takemitsu Asaoka
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 3.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

4.  Oral itraconazole in treatment of candidemia in a pediatric intensive care unit.

Authors:  Sunit C Singhi; Thimmapuram C S Reddy; Arunaloke Chakrabarti
Journal:  Indian J Pediatr       Date:  2004-11       Impact factor: 1.967

Review 5.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 6.  In search of the holy grail of antifungal therapy.

Authors:  Stanley W Chapman; Donna C Sullivan; John D Cleary
Journal:  Trans Am Clin Climatol Assoc       Date:  2008

7.  High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections.

Authors:  Lixin Zhang; Kezhi Yan; Yu Zhang; Ren Huang; Jiang Bian; Chuansen Zheng; Haixiang Sun; Zhihui Chen; Nuo Sun; Rong An; Fangui Min; Weibo Zhao; Ying Zhuo; Jianlan You; Yongjie Song; Zhenyan Yu; Zhiheng Liu; Keqian Yang; Hong Gao; Huanqin Dai; Xiaoli Zhang; Jian Wang; Chengzhang Fu; Gang Pei; Jintao Liu; Si Zhang; Michael Goodfellow; Yuanying Jiang; Jun Kuai; Guochun Zhou; Xiaoping Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

Review 8.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 9.  Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Authors:  R N Brogden; K L Goa; A J Coukell
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

10.  Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study.

Authors:  David M Jacobs; Thomas J Dilworth; Nicholas D Beyda; Anthony M Casapao; Dana R Bowers
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.